Abstract. Genetic mutations on signaling pathways are found in patients with T-cell acute lymphoblastic leukemia (T-ALL) and act as markers of high-risk leukemia. Mutations in dynamin 2 (DNM2) have been reported in T-ALL, particularly in early T-cell precursor-ALL. In the present study, DNM2 mutations were screened by sequencing DNM2 exons obtained by polymerase chain reaction amplification and gel purification in adult T-ALL patients. A total of 4 novel DNM2 mutations were identified in adult T-ALL patients, with a mutation rate of 9.5%, and the DNM2 mutations were found to co-exist with NOTCH1 and PHD finger protein 6, and were also associated with high-risk leukemia. A high rate of silent mutation was also found in the patients, but no significant association was found between the silent mutations and patients' clinical features. The present findings suggested the DNM2 mutations may be involved in the oncogenesis of T-ALL.
Introduction
Acute lymphoblastic leukemia (ALL) is the most common malignancy in B cells, immature T lymphocytes or lymphoid progenitors (1) . T-cell acute lymphoblastic leukemia (T-ALL) accounts for ~15 and 25% of ALL in pediatric and adult patients, respectively (2) . Patients with T-ALL usually have high white blood cell (WBC) counts and may present with organomegaly, particularly mediastinal enlargement and central nervous system (CNS) involvement (3) . The biological knowledge of T-ALL is limited. Previously, T-ALL was classified into five subgroups (pro-T, pre-T, cortical, mature T-ALL and ETP) based on the results of fluorescent in situ hybridization (FISH), molecular biology and gene expression profiling (4) . With exome-sequencing and whole genome sequencing, genetic mutations on genes including NOTCH1, F-box and WD repeat domain containing 7 (FBXW7), Ras, PHD finger protein 6 (PHF6) and Janus kinase 1 (JAK1) have been found to be high-risk markers in patients with T-ALL (3, 5, 6) .
The GTPase dynamin 2 (DNM2) is essential for intracellular vesicle formation and trafficking, cytokinesis and receptor endocytosis. DNM2 contains five domains, as follows: GTPase domain; intermediate domain (MD); pleckstrin homology domain (PH); GTPase effector domain (GED); and proline-arginine-rich domain (PRD). High DNM2 expression is observed in prostate cancer and associated with cancer progression (7) . DNM2 potentiates invasive migration of pancreatic tumor cells (8) . Inhibition of DNM2 induced cell death in 11 cancer cell lines (9) . Previously, DNM2 genetic mutations were identified in a subtype of T-ALL, termed early T-cell precursor (ETP) ALL, which accounts for up to 15% of T-ALL and is associated with a high risk of treatment failure (6, 10) . However, to the best of our knowledge, no studies have investigated DNM2 genetic mutations in adult ALL. The present study sequenced the exons of DNM2 genes in 42 patients with T-ALL, and the clinical features in the patients with DNM2 mutations were analyzed. ) samples from  42 patients with newly diagnosed T-ALL, consisting of  31 male patients with a median age of 26 years (range,  16-62 years) and 11 female patients with a median age  of 29 years (range, 19-60 years) , were collected between July 2010 and December 2014 at the First Affiliated Hospital of Nanjing Medical University (Nanjing, Jiangsu, China). The diagnosis of ALL was made according to the morphological, immunophenotypical, cytogenetic and molecular criteria of the 2008 World Health Organization Diagnosis and Classification of ALL (11) . All patients provided written informed consent, in accordance with the Declaration of Helsinki, prior to enrollment in the study. The present study was approved by the Institutional Review Board of Nanjing Medical University.
Materials and methods

Patients and samples. Bone marrow (BM
Mutational analysis of DNM2. Mutational analysis of DNM2 exons 2-22 was performed. Genomic DNA was isolated using a Wizard ® Genomic DNA Purification kit (Promega Corporation, Madison, WI, USA) according to the manufacturer's protocol. DNA fragments spanning the aforementioned DNM2 exons were amplified by PCR using AmpliTaq Gold kit (Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and exon-specific primers. The primers for PCR amplification of DNM2 exons were as follows: exon 2 forward, TGC AAG ACA GAG TTG CTC CAC and reverse, TGT GTA AGT GTT CAC TGA GCCG; exon 3 forward, CCA GCC TGG GTC ATT ACT TTC and reverse, ACA CAG GCT CAC CCA TAG CAC; exon 4 forward, GTG GTT CAG GCA GAG TGT CAG and reverse, GAC TTG GAA CCA AGG ATG CTG; exon 5 forward, CTG TGA GAT CAG GGC TGT GAC and reverse, GGA GAA GCA ATG ACT TCC AGG; exon 6 forward, TAC TTG AAT CTT GCC CAT CCC and reverse, CTG AAA CAA GTG CCA GTG AGG; exon 7 forward, ATA GTG GCA CCC TGG TGT TG and reverse, GTG GAC GAG TGA TGA GTG GTG; exon 8 forward, GTA AAC CCT GGC TTG ACT TGG and reverse, CTT GAG ACC TTA TTG CCT GGG; exon 9 forward, GTG TGA GCC ACT GTA TCT GGC and reverse, GGA CTC AGA GGT GTG GGT GAC; exon 10 forward, CAA CCT TCA TTC CTT GTT GGG and reverse, CTG GGA GCC TGA TAC CAA ACC; exon 12 forward, TCT TCT GCT CTT AGC TCC CAG and reverse, TGT CAG CAT GCA CAG AAC AGT; exon 13 forward, TCT GTT GCC TAT GAG GGT GTG and AAT CCC AAC TCA GTC ACC TCC; exon 14 forward, CTA CCT GTG GCT GCT CAC TTG and reverse, TAG AGA GAG CAG ATG GCC TGG; exon 16 forward, GGG CTG GAG GTG TCT CTA TTG and reverse, GCA GTG ACT GAG TTC TGC CC; exon 17 forward, TCA TAT ACA GCA GCG ACC AGC and reverse, GTG CTC AGT GCT CAG TGA AGG; exon 18 forward, CTA GAG CCC ATT CCT CTC GG and reverse, CAT GAT TTC AGA GAC TCC TGGC; exon 19 forward, TAG GGC AGA TGG TTT CCA GAG and reverse, CTC CTT AGC TCG TGA TCC GC; exon 20 forward, CCC GCC CTG TGA GAG ATG and reverse, AGG ACC CTG CAG GAC ACAC; exon 21 forward, CAC CTC AGG TTC TGG CAGC and reverse, ACT GGG AGG AAG TGA GAC AGG; and exon 22 forward, GAG TTG ATG CCT AGG TTT GGC and reverse GAG CCT GGT CCC AGC ATAG. Exons in NOTCH1, FBXW7, PHF6, phosphatase and tensin homolog (PTEN), JAK1 and interleukin (IL)-7R were also amplified as previously reported (11) (12) (13) (14) (15) Cytogenetic and molecular analyses. Conventional cytogenetic analysis was performed at the time of diagnosis, using unstimulated short-term cultures, according to the recommendations of the International System for Human Cytogenetic Nomenclature (16) . For each sample, at least 20 BM metaphase cells were analyzed.
Immunophenotypical analyses were performed by flow cytometry on fresh BM samples as described previously (17, 18) . The following antibody conjugates were used: anti-cluster of differentiation (CD)3-fluorescein isothiocyanate (FITC; catalog no., 555339), anti-CD2-allophycocyanin (APC; catalog no., 560642), anti-CD5-phycoerythrin (PE; catalog no., 555353), anti-CD7-brilliant violet 421 (BV421; catalog no., 562635), anti-CD19-FITC (catalog no., 555412), anti-CD20-APC (catalog no., 559776), anti-CD10-BV421 (catalog no., 562902), anti-CD34-PE (catalog no., 555822) and anti-CD33-BV605 (catalog no., 740400). All the antibodies were mouse antihuman and purchased from BD Biosciences (San Jose, CA, USA) and used for cell staining according to the manufacturer's protocol. FITC, PE, BV605 and BV421-conjugated antibodies were diluted 1:5; APC-conjugated antibodies were diluted 1:20. The stained cells were analyzed on a FACScalibur flow cytometer (BD Biosciences), which was equipped with red and blue lasers. Routine machine calibration was performed daily according to the standard operating procedures of our laboratory. Fluorescence compensation calibration was run at least once a week using standard fluorescence beads (Calibrite beads; BD Biosciences). Data analysis was performed using BD CellQuest™ Pro software version 6.0 (BD Biosciences), and lymphocytes were delineated using forward scatter/side scatter dot plots. Cell-surface antigens were defined as present when the fluorescence intensity of ≥20% of cells exceeded the fluorescence of the negative control.
Statistical analysis. For qualitative parameters, overall group differences were analyzed using a χ 2 test. All statistical analyses were performed using SPSS version 17.0 (SPSS, Inc., Chicago, IL, USA). P<0.05 was considered to indicate statistical significance.
Results
Mutational analysis of DNM2. DNM2 mutations were identified in 4 out of 42 T-ALL patients, resulting in a mutation incidence of 9.5%. The 4 mutations were the point mutations c.1081C>T, c.1453T>C, c.1609G>A and c.1801C>T, which were located in exons 8, 13, 16 and 18, respectively. In the 4 mutations, 1 mutation was a nonsense mutation and 3 mutations were missense mutations. All 4 mutations led to amino acid changes (R361X, Y485H, G537S and R601W). The R361X and Y485H mutations are located within the DNM2 MD; G537S and R601W mutations are located within the DNM2 PH domain (Fig. 1) .
DNM2 mutation in combination with NOTCH1 and PHF6
mutation. The present study found that in these 4 patients, DNM2 mutations co-existed with NOTCH1 mutations. In 3 of the 4 patients, the DNM2 mutation co-existed with two NOTCH1 mutations (point mutations and/or indel mutations) located in NOTCH1 exons 26, 27 and 34. In addition, 3 of the 4 patients with DNM2 mutations had PHF6 mutations located in PHF6 exons 4, 5 and 8 (Table I) . Table III) . The clinical features of the patients with DNM2 synonymous amino acid mutations were also observed, but these synonymous amino acid mutations were not significantly associated with any clinical features observed (data not shown).
Discussion
The DNM2 protein is involved in a wide range of cellular functions, including phagocytosis, phagosome formation of actin and microtubule interactions, cytokinesis, cell migration and regulation of apoptosis (19) . It has been reported that DNM2 gene mutation is an important factor for patients with autosomal dominant centronuclear myopathy (20) and Alzheimer's disease (21, 22) . Recurrent DNM2 mutations have also been identified in patients with ETP-ALL by whole-exome sequencing (6, 10, 23) . These mutations include: E78fs in the Ras-like GTPase domain; L3354P, R364C, K382E, T404N and E468 * in the dynamin MD domain; S528fs, E544fs and K557_K558>K in the PH domain; S698L in the GTPase effector domain; and K770 * , P791T, L789fs and I805fs in the C-terminus. In addition, it has been shown that certain mutations appear in patients that experience relapse with induction failure. The present study identified 4 novel DNM2 mutations in 42 adult T-ALL patients, with a mutation rate of 9.5%. These mutations also mainly appear in the dynamin central region (MD domain), PH domain and GTPase effector domains. It was also found that the patients with DNM2 mutations were more likely to demonstrate high-risk factors, such as a high WBC count, complex karyotype, lymph node infiltration and difficulty achieving complete remission. These data indicated that patients with T-ALL with DNM2 mutations have a poor outcome.
Patient Mu1# was diagnosed with a type of hypoproliferative leukemia termed 'hypocellular leukemia', with less tolerance to Table I . Co-existence of DNM2, NOTCH1 and PHF6 mutations in adult patients with T-cell acute lymphoblastic leukemia. chemotherapy and poor clinical outcome compared to individual's with normal/increased WBC counts. Hypocelluar leukemia is most commonly observed in cases of acute myeloid leukemia, and certain cases are secondary leukemia resulting from myelodysplastic syndrome, indicating high-risk leukemia (24, 25) . The mechanism of hypoproliferative leukemia is not fully understood. The present study identified that 5 immunotypes were present in patient Mu2#, but only 2-3 immunotypes were present in the other 3 patients with detected mutations. Only CD33 was observed in patient Mu2#, suggesting this immunotype may lead to a poorer outcome compared with those observed in the other 3 patients. In addition, the association of the mutations with survival of the patients requires clarification with more patients with the mutations in future. Table II . Clinical characteristics of T-ALL patients with DNM2 mutations. Cell-surface antigens were defined as present when the fluorescence intensity of ≥20% of cells exceeded the fluorescence of the negative control. F, female; M, male; T-ALL, T-cell acute lymphoblastic leukemia; DNM2, dynamin 2; WBC, white blood cell; HGB, hemoglobin; PLT, platelet; LDH, lactate dehydrogenase; CD, cluster of differentiation; TCR, T cell receptor.
DNM2 can bind to membrane phospholipids through PH domains and the endogenous GED can activate GTPase activity. In addition, high DNM2 expression is associated with a poor prognosis and high rate of metastasis in patients with solid cancer. Inhibition of DNM2 induces the apoptosis of cancer cells (8) (9) (10) . Therefore, the present authors hypothesize that the DNM2 mutations identified in the present study may be gain-of-function mutations. The effects of these newly-identified DNM2 mutations on the proliferation of leukemia cells in the current study may be examined in future studies.
Notably, a high rate of DNM2 synonymous amino acid mutations (also termed silent mutations) was identified in the patients. Silent mutations are the evolutionary substitution of one base for another in an exon of a gene coding for a protein, such that the produced amino acid sequence is not modified. However, mutations do not always result in silent mutations (26) (27) (28) . The point mutation may affect transcription, splicing, mRNA transport and translation, any of which may alter the phenotype, rendering the synonymous mutation non-silent (26) (27) (28) .
In the present study, DNM2 expression was not observed in the patients with DNM2 silent mutations, and no significant changes in DNM2 expression were found in the patients with silent mutations compared to patients without mutations. In addition, no significant association between the DNM2 silent mutations and any clinical features was observed. These data indicated that the sites with silent mutations may only be the hot spots and the nucleotides in these sites are easily changed, but the nucleotide changes may also be quickly corrected. The clinical relevance of DNM2 silent mutations requires additional clarification. It was hypothesized in the present study that silent mutations may affect DNM2 translation in patients (26) (27) (28) .
In summary, the present study identified 4 novel DNM2 mutations in T-ALL and their associations with high-risk leukemia. The current findings suggest the DNM2 mutations may be involved in the oncogenesis of T-ALL.
